

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/051497-Conf. #1774
	Filing Date	January 18, 2002
	First Named Inventor	Rong-Hwa Lin
	Art Unit	1644
	Examiner Name	P. Gambel
Total Number of Pages in This Submission	Attorney Docket Number	A0871.70000US01

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement/PTO Form 1449 with references <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
<b>Remarks</b>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	Alan W. Steele, M.D., Ph.D.		
Date	August 1, 2006	Reg. No.	45,128

**Certificate of Mailing Under 37 CFR 1.8(a)**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: 1 August 2006

Signature:

(Alan W. Steele, M.D., Ph.D.)



DOCKET NO.: A0871.70000US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rong-Hwa Lin et al.  
Serial No.: 10/051497  
Confirmation No.: 1774  
Filed: January 18, 2002  
For: METHODS OF MODULATING T CELL OR NATURAL  
KILLER CELL ACTIVITY WITH ANTI-P-SELECTIN  
GLYCOPROTEIN LIGAND 1 ANTIBODIES

Examiner: Phillip Gambel  
Art Unit: 1644

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 1st day of August, 2006.

Alan W. Steele, M.D., Ph.D., Reg. No. 45,128

---

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

**PART I: Compliance with 37 C.F.R. §1.97**

This Information Disclosure Statement has been filed before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Attorney Docket No.</u>
10/662,906	09/15/2003	Rong-Hwa Lin et al.	A0871.70001US00
11/125,837	05/10/2005	Rong-Hwa Lin et al.	A0871.70002US01
11/127,804	05/11/2005	Rong-Hwa Lin et al.	A0871.70003US02

The Applicant would like to bring to the Examiner's attention the enclosed search report from related International Application No. PCT/US04/29520.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

Serial No.: 10/051497  
Conf. No.: 1774

- 3 -

Art Unit: 1644

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By:




---

Alan W. Steele, M.D., Ph.D.  
Reg. No. 45,128  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: A0871.70000US01  
Date: August 1, 2006  
xNDDx

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		APPLICATION NO.: 10/051497	ATTY. DOCKET NO.: A0871.70000US01
		FILING DATE: January 18, 2002	CONFIRMATION NO.: 1774
		APPLICANT: Rong-Hwa Lin et al.	
		GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	2		



### U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		5,378,464		McEver	01-03-1995
		5,618,785		Heavner et al.	04-08-1997
		5,709,859		Aruffo et al.	01-20-1998
		5,710,123		Heavner et al.	01-20-1998
		5,808,025		Tedder et al.	09-15-1998
		5,834,425		Tedder et al.	11-10-1998
		5,972,625		Rosen et al.	10-26-1999
		6,056,956		Cobbold et al.	05-02-2000
		6,309,639		Cummings et al.	10-30-2001
		2002-0164336	A1	Harrison et al.	11-07-2002
		6,667,036		Cummings et al.	12-23-2003

### FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		HERRON MJ et al., Intracellular parasitism by the human granulocytic ehrlichiosis bacterium through the P-selectin ligand, PSGL-1. <i>Science</i> . 2000 Jun 2;288(5471):1653-6.	
		LI F et al., Visualization of P-selectin glycoprotein ligand-1 as a highly extended molecule and mapping of protein epitopes for monoclonal antibodies. <i>J. Biol. Chem.</i> 271(11):6342-6348 (1996).	
		MOORE KL et al., P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. <i>J. Cell Biol.</i> 128(4):661-671 (1995).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/051497	ATTY. DOCKET NO.: A0871.70000US01
				FILING DATE: January 18, 2002	CONFIRMATION NO.: 1774
				APPLICANT: Rong-Hwa Lin et al.	
				GROUP ART UNIT: 1644	EXAMINER: Phillip Gambel
Sheet	2	of	2		

		SAKO D et al., Expression cloning of a functional glycoprotein ligand for P-selectin. <i>Cell</i> . 1993 Dec 17;75(6):1179-86.	
		TREMBLEAU S et al., Pancreas-infiltrating Th1 cells and diabetes develop in IL-12-deficient nonobese diabetic mice. <i>J Immunol</i> . 1999 Sep 1;163(5):2960-8.	
		VACHINO G et al., P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells. <i>J Biol Chem</i> . 1995 Sep 15;270(37):21966-74.	
		VELDMAN GM et al., Genomic organization and chromosomal localization of the gene encoding human P-selectin glycoprotein ligand. <i>J Biol Chem</i> . 1995 Jul 7;270(27):16470-5.	
		WU P et al., Role of P-selectin and anti-P-selectin monoclonal antibody in apoptosis during hepatic/renal ischemia reperfusion injury. <i>World J. Gastroentero</i> 6(2):244-247 (2000).	
		YAGO T et al., IL-12 promotes the adhesion of NK cells to endothelial selectins under flow conditions. <i>J Immunol</i> . 1998 Aug 1;161(3):1140-5.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

# EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]